LUND, SE / ACCESS Newswire / May 19, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)Spago Nanomedical's annual report for 2025 is from today available at the company's website, https://spagonanomedical.se/investor-relations/#financial-reportsFor further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.seSpago Nanomedical AB is a Swedish company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise treatment and diagnosis of cancer and other debilitating diseases. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.FNCA Sweden AB is the Certified Adviser of the company.AttachmentsSpago Nanomedical AB Annual Report 2025SOURCE: Spago NanomedicalView the original press release on ACCESS Newswire
The articles, information, and content displayed on this webpage may
include materials prepared and provided by third parties. Such
third-party content is offered for informational purposes only and
is not endorsed, reviewed, or verified by Morningstar.
